WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering

Rhea-AI Summary

bioAffinity Technologies (Nasdaq:BIAF) closed a previously announced public offering for $3.2 million in aggregate gross proceeds, before fees and expenses.

The offering comprised 4,000,000 common shares at $0.80 per share, or pre-funded warrants at $0.793, each exercisable for one common share. WallachBeth Capital acted as sole placement agent.

Positive

• $3.2 million aggregate gross proceeds raised before fees and expenses
• Issuance of 4,000,000 common shares or pre-funded warrants expands capital base
• Pre-funded warrants are immediately exercisable, providing funding flexibility

Negative

• Offering of 4,000,000 new common shares implies shareholder dilution
• Gross proceeds are stated before agent fees and expenses, reducing net cash received

News Market Reaction – BIAF

-1.55%

-1.55% News Effect

On the day this news was published, BIAF declined 1.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms closing of a $3.2 million equity financing at $0.80 per share, consistent...

Analysis

This announcement confirms closing of a $3.2 million equity financing at $0.80 per share, consistent with BIAF’s prior offerings that averaged moves of -10.14%. Investors may watch balance-sheet runway and any future capital-raising plans.

Key Figures

Gross proceeds: $3.2 million Shares offered: 4,000,000 shares Common share price: $0.80 per share +2 more

5 metrics

Gross proceeds $3.2 million Aggregate gross proceeds from this public offering before fees

Shares offered 4,000,000 shares Common stock (or pre-funded warrants in lieu) in this deal

Common share price $0.80 per share Purchase price for common stock in the offering

Pre-funded warrant price $0.793 per warrant Purchase price for pre-funded warrants in the offering

Par value $0.007 per share Par value of BIAF common stock

Previous Offering Reports

5 past events · Latest: Jun 17 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 17	Offering pricing	Negative	-12.0%	Registered public offering priced for $3.2M gross proceeds before expenses.
Jun 17	Offering pricing	Negative	-12.0%	Public offering priced at $0.80 per share or $0.793 per warrant.
Sep 30	Offering closing	Negative	-8.9%	Completion of $4.8M public offering of common stock and pre-funded warrants.
Sep 30	Offering closing	Negative	-8.9%	Company announced closing of $4.8M public equity financing round.
Sep 29	Offering pricing	Negative	-8.9%	Pricing of $4.8M public offering at $2.50 per share or $2.493 warrant.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Equity offering announcements for BIAF have repeatedly coincided with sizable negative price reactions.

Key Terms

pre-funded warrants, registration statement on form s-1, prospectus, placement agent

4 terms

pre-funded warrants financial

"or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registration statement on form s-1 regulatory

"pursuant to a registration statement on Form S-1 (File No. 333-296764)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering was made only by means of a preliminary prospectus and final prospectus"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

placement agent financial

"WallachBeth Capital, LLC acted as sole placement agent for the offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.

The offering consisted of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for one share of common stock and will be immediately exercisable and will expire when exercised in full.

The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions.

WallachBeth Capital, LLC acted as sole placement agent for the offering.

The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-296764), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

About WallachBeth Capital LLC:

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-3-2-million-offering-302804798.html

SOURCE WallachBeth Capital LLC

FAQ

What did bioAffinity Technologies (BIAF) announce about its June 2026 offering?

bioAffinity Technologies announced the closing of a public offering for $3.2 million in gross proceeds. According to bioAffinity Technologies, the deal includes common stock and pre-funded warrants, with WallachBeth Capital serving as sole placement agent.

How many shares were issued in the bioAffinity Technologies (BIAF) $3.2 million offering?

The offering consisted of 4,000,000 shares of common stock, or pre-funded warrants in lieu of shares. According to bioAffinity Technologies, each pre-funded warrant is exercisable for one common share at $0.793 per warrant.

What was the offering price for bioAffinity Technologies (BIAF) June 2026 financing?

bioAffinity Technologies priced its common stock at $0.80 per share and pre-funded warrants at $0.793. According to bioAffinity Technologies, each pre-funded warrant is immediately exercisable for one common share and remains outstanding until exercised in full.

When is the closing of bioAffinity Technologies (BIAF) $3.2 million offering expected?

The closing of the offering is expected on or about June 18, 2026, subject to customary closing conditions. According to bioAffinity Technologies, the securities were issued under an effective Form S-1 registration statement filed with the SEC.

How might the $3.2 million stock offering affect bioAffinity Technologies (BIAF) shareholders?

The issuance of 4,000,000 new shares or pre-funded warrants increases the company’s share count, which can dilute existing holdings. According to bioAffinity Technologies, the transaction provides additional gross proceeds before fees and expenses.

Who acted as placement agent for bioAffinity Technologies (BIAF) June 2026 offering?

WallachBeth Capital served as sole placement agent for the offering. According to bioAffinity Technologies, investors could access the prospectus electronically or by contacting WallachBeth Capital’s capital markets group in Jersey City, New Jersey.